Costa, L., Godby, K., Ravi, G., Huls, F., Medvedova, E., Dhakal, B., Dholaria, B., Callander, N., Silbermann, R., Joiner, L., Hagedorn, C., Mullinax, B., Bal, S. (2025). Distinct trajectory and prognosis of measurable residual disease (MRD) in t(11;14) multiple myeloma (MM) treated with upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT). Blood. https://doi.org/10.1182/blood-2025-363